COMMUNIQUÉ DE PRESSE publié le 03/04/2025 à 07:00, il y a 1 année 7 mois “Tunnel Ostbahnhof” joint venture awarded contract for eastern section of the Second Core S-Bahn Route in Munich Implenia AG's joint venture awarded major contract for 'Tunnel Ostbahnhof' project as part of the Second Core S-Bahn Route in Munich, worth hundreds of millions of euros. Construction begins in June 2025 and aims for completion by May 2033 Implenia AG Munich Deutsche Bahn Tunnel Ostbahnhof Second Core S-Bahn Route
COMMUNIQUÉ DE PRESSE publié le 03/04/2025 à 07:00, il y a 1 année 7 mois Holcim acquires Compañía Minera Luren to expand in Latin America Holcim acquires Compañía Minera Luren, leading Peruvian producer of high-value building solutions, to expand in Latin America and accelerate growth. Acquisition expected to generate synergies in Peru and Latin America Acquisition Latin America Holcim Building Solutions Compañía Minera Luren
COMMUNIQUÉ DE PRESSE publié le 03/04/2025 à 07:00, il y a 1 année 7 mois Multitude AG Preliminary Unaudited 2024 Results Highlighting Strong Growth and Profitability Multitude AG reports preliminary unaudited 2024 results with 14.4% revenue growth to EUR 263.7 million and 48.5% jump in EBIT to EUR 67.6 million. Strong profitability demonstrated Revenue Growth Financial Performance Profitability Preliminary Results Multitude AG
COMMUNIQUÉ DE PRESSE publié le 03/04/2025 à 07:00, il y a 1 année 7 mois Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares contre lesquelles il n’existe aucun médicament approuvé Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares, l'anémie hémolytique à anticorps chauds et la maladie associée aux IgG4, sans traitement approuvé actuellement FDA Traitement Maladies Rares Médicament Orphelin Rilzabrutinib
COMMUNIQUÉ DE PRESSE publié le 03/04/2025 à 07:00, il y a 1 année 7 mois Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Rilzabrutinib granted orphan drug designation in the US for warm autoimmune hemolytic anemia and IgG4-related disease, potential use in immune thrombocytopenia. Sanofi's novel BTK inhibitor holds promise for rare diseases Orphan Drug Designation Sanofi Rare Diseases Rilzabrutinib BTK Inhibitor
COMMUNIQUÉ DE PRESSE publié le 03/04/2025 à 06:59, il y a 1 année 7 mois grenke achieves very profitable new business in Q1 2025 grenke AG reports a 10.6% growth in leasing new business to EUR 740.6 million and a 15.6% increase in Contribution Margin 2 in Q1 2025, aiming to enhance profitability and market leadership Profitability Leasing GRENKE AG New Business CM2
COMMUNIQUÉ DE PRESSE publié le 03/04/2025 à 06:59, il y a 1 année 7 mois Aperam update on Q1 2025 market & financial trends Aperam provides an update on Q1 2025 market & financial trends ahead of the quarterly results release. Details on EBITDA, acquisitions, cash flow, and market outlook included Market Trends Aperam Earnings Guidance Financial Update Q1 2025
COMMUNIQUÉ DE PRESSE publié le 03/04/2025 à 06:59, il y a 1 année 7 mois Aperam update on Q1 2025 market & financial trends Aperam provides update on Q1 2025 market & financial trends including adjusted EBITDA, pricing pressure, net debt, and operational highlights Aperam Market Update Financial Trends Q1 2025 Earnings Drivers
COMMUNIQUÉ DE PRESSE publié le 03/04/2025 à 06:40, il y a 1 année 7 mois Ad hoc announcement pursuant to Art. 53 LR: Jungfraubahn Holding AG: Jungfrau Railway Group reports a successful 2024 financial year Jungfraubahn Holding AG announces a successful 2024 financial year with increased transport income and proposal to raise dividend. Jungfraujoch and Experience Mountains segments show strong performance Dividend Proposal Jungfraubahn Holding AG 2024 Financial Year Segment Performance Transport Income
COMMUNIQUÉ DE PRESSE publié le 03/04/2025 à 05:10, il y a 1 année 7 mois Battery X Metals Announces Corporate Awareness Agreement Battery X Metals Inc. engages bullVestor for marketing services to increase awareness among European investment community. Explore more at batteryxmetals.com Energy Transition Marketing Services Battery X Metals European Investment BullVestor
Publié le 10/11/2026 à 18:00, il y a 1 heure 35 minutes Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Publié le 10/11/2026 à 17:45, il y a 1 heure 50 minutes Damartex / Descriptif du programme de rachat d'actions
Publié le 10/11/2026 à 17:35, il y a 2 heures ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Publié le 10/11/2026 à 17:31, il y a 2 heures 3 minutes CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
Publié le 10/11/2026 à 14:45, il y a 4 heures 50 minutes An Investigational Drug to Tackle Measles Outbreaks
Publié le 10/11/2026 à 14:31, il y a 5 heures 4 minutes First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
Publié le 10/11/2026 à 14:30, il y a 5 heures 5 minutes Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
Publié le 10/11/2026 à 14:30, il y a 5 heures 5 minutes ACCESS Newswire Reports Third Quarter 2026 Results
Publié le 10/11/2026 à 14:00, il y a 5 heures 35 minutes Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
Publié le 10/11/2026 à 19:21, il y a 13 minutes ALTHEORA, Mäder Composites France et IPC s'associent pour donner une seconde vie aux matériaux composites
Publié le 10/11/2026 à 18:54, il y a 40 minutes REPLOID Group AG pursues entry in the US market and secures exclusivity to conduct due diligence for the potential acquisition of Chapul, LLC.
Publié le 10/11/2026 à 18:45, il y a 50 minutes Special Optics Introduces Purpose-Built Microscope Objectives for Quantum Applications
Publié le 10/11/2026 à 18:30, il y a 1 heure 5 minutes Shelly Group Accelerates Revenue Growth in the Third Quarter and Confirms Full-Year 2026 Guidance